vs
Avantor, Inc.（AVTR）与布鲁克（BRKR）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是布鲁克的1.7倍（$1.7B vs $977.2M）。Avantor, Inc.净利率更高（3.1% vs 2.7%，领先0.5%）。布鲁克同比增速更快（-0.2% vs -1.4%）。布鲁克自由现金流更多（$207.2M vs $117.2M）。过去两年布鲁克的营收复合增速更高（16.4% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
布鲁克公司是美国科学仪器制造商，总部位于马萨诸塞州比勒里卡，为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域，旗下设有布鲁克科学仪器、布鲁克能源与超导技术（BEST）两大业务板块。
AVTR vs BRKR — 直观对比
营收规模更大
AVTR
是对方的1.7倍
$977.2M
营收增速更快
BRKR
高出1.1%
-1.4%
净利率更高
AVTR
高出0.5%
2.7%
自由现金流更多
BRKR
多$90.0M
$117.2M
两年增速更快
BRKR
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $977.2M |
| 净利润 | $52.4M | $26.0M |
| 毛利率 | 31.5% | 46.0% |
| 营业利润率 | 7.6% | 7.8% |
| 净利率 | 3.1% | 2.7% |
| 营收同比 | -1.4% | -0.2% |
| 净利润同比 | -89.5% | 89.8% |
| 每股收益（稀释后） | $0.08 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRBRKR
| Q4 25 | $1.7B | $977.2M | ||
| Q3 25 | $1.6B | $860.5M | ||
| Q2 25 | $1.7B | $797.4M | ||
| Q1 25 | $1.6B | $801.4M | ||
| Q4 24 | $1.7B | $979.6M | ||
| Q3 24 | $1.7B | $864.4M | ||
| Q2 24 | $1.7B | $800.7M | ||
| Q1 24 | $1.7B | $721.7M |
净利润AVTRBRKR
| Q4 25 | $52.4M | $26.0M | ||
| Q3 25 | $-711.8M | $-59.6M | ||
| Q2 25 | $64.7M | $7.6M | ||
| Q1 25 | $64.5M | $17.4M | ||
| Q4 24 | $500.4M | $13.7M | ||
| Q3 24 | $57.8M | $40.9M | ||
| Q2 24 | $92.9M | $7.6M | ||
| Q1 24 | $60.4M | $50.9M |
毛利率AVTRBRKR
| Q4 25 | 31.5% | 46.0% | ||
| Q3 25 | 32.4% | 44.1% | ||
| Q2 25 | 32.9% | 44.9% | ||
| Q1 25 | 33.8% | 48.8% | ||
| Q4 24 | 33.4% | 50.4% | ||
| Q3 24 | 32.9% | 48.4% | ||
| Q2 24 | 34.1% | 48.0% | ||
| Q1 24 | 34.0% | 48.9% |
营业利润率AVTRBRKR
| Q4 25 | 7.6% | 7.8% | ||
| Q3 25 | -40.0% | -6.0% | ||
| Q2 25 | 7.7% | 1.5% | ||
| Q1 25 | 9.3% | 4.0% | ||
| Q4 24 | 37.8% | 7.4% | ||
| Q3 24 | 7.3% | 7.9% | ||
| Q2 24 | 10.3% | 6.0% | ||
| Q1 24 | 8.7% | 9.0% |
净利率AVTRBRKR
| Q4 25 | 3.1% | 2.7% | ||
| Q3 25 | -43.8% | -6.9% | ||
| Q2 25 | 3.8% | 1.0% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 29.7% | 1.4% | ||
| Q3 24 | 3.4% | 4.7% | ||
| Q2 24 | 5.5% | 0.9% | ||
| Q1 24 | 3.6% | 7.1% |
每股收益（稀释后）AVTRBRKR
| Q4 25 | $0.08 | $0.10 | ||
| Q3 25 | $-1.04 | $-0.41 | ||
| Q2 25 | $0.09 | $0.05 | ||
| Q1 25 | $0.09 | $0.11 | ||
| Q4 24 | $0.73 | $0.09 | ||
| Q3 24 | $0.08 | $0.27 | ||
| Q2 24 | $0.14 | $0.05 | ||
| Q1 24 | $0.09 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $298.8M |
| 总债务越低越好 | $3.9B | $1.9B |
| 股东权益账面价值 | $5.6B | $2.5B |
| 总资产 | $11.8B | $6.2B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.76× |
8季度趋势，按日历期对齐
现金及短期投资AVTRBRKR
| Q4 25 | $365.4M | $298.8M | ||
| Q3 25 | $251.9M | $293.1M | ||
| Q2 25 | $449.4M | $92.0M | ||
| Q1 25 | $315.7M | $184.2M | ||
| Q4 24 | $261.9M | $183.4M | ||
| Q3 24 | $285.3M | $148.1M | ||
| Q2 24 | $272.6M | $169.7M | ||
| Q1 24 | $234.9M | $340.1M |
总债务AVTRBRKR
| Q4 25 | $3.9B | $1.9B | ||
| Q3 25 | $3.9B | $2.0B | ||
| Q2 25 | $4.2B | $2.4B | ||
| Q1 25 | $4.1B | $2.1B | ||
| Q4 24 | $4.1B | $2.1B | ||
| Q3 24 | $4.9B | $2.3B | ||
| Q2 24 | $5.1B | $2.2B | ||
| Q1 24 | $5.3B | $1.4B |
股东权益AVTRBRKR
| Q4 25 | $5.6B | $2.5B | ||
| Q3 25 | $5.6B | $2.4B | ||
| Q2 25 | $6.3B | $1.8B | ||
| Q1 25 | $6.1B | $1.8B | ||
| Q4 24 | $6.0B | $1.8B | ||
| Q3 24 | $5.6B | $1.8B | ||
| Q2 24 | $5.4B | $1.8B | ||
| Q1 24 | $5.3B | $1.4B |
总资产AVTRBRKR
| Q4 25 | $11.8B | $6.2B | ||
| Q3 25 | $11.7B | $6.4B | ||
| Q2 25 | $12.8B | $6.3B | ||
| Q1 25 | $12.3B | $5.9B | ||
| Q4 24 | $12.1B | $5.8B | ||
| Q3 24 | $12.8B | $6.1B | ||
| Q2 24 | $12.7B | $5.9B | ||
| Q1 24 | $12.8B | $4.5B |
负债/权益比AVTRBRKR
| Q4 25 | 0.71× | 0.76× | ||
| Q3 25 | 0.69× | 0.83× | ||
| Q2 25 | 0.67× | 1.34× | ||
| Q1 25 | 0.67× | 1.15× | ||
| Q4 24 | 0.68× | 1.18× | ||
| Q3 24 | 0.89× | 1.27× | ||
| Q2 24 | 0.94× | 1.21× | ||
| Q1 24 | 1.00× | 0.97× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $229.8M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $207.2M |
| 自由现金流率自由现金流/营收 | 7.0% | 21.2% |
| 资本支出强度资本支出/营收 | 2.1% | 2.3% |
| 现金转化率经营现金流/净利润 | 2.91× | 8.84× |
| 过去12个月自由现金流最近4个季度 | $495.0M | $43.3M |
8季度趋势，按日历期对齐
经营现金流AVTRBRKR
| Q4 25 | $152.7M | $229.8M | ||
| Q3 25 | $207.4M | $-33.2M | ||
| Q2 25 | $154.4M | $-127.5M | ||
| Q1 25 | $109.3M | $65.0M | ||
| Q4 24 | $173.3M | $190.0M | ||
| Q3 24 | $244.8M | $38.4M | ||
| Q2 24 | $281.1M | $1.1M | ||
| Q1 24 | $141.6M | $21.8M |
自由现金流AVTRBRKR
| Q4 25 | $117.2M | $207.2M | ||
| Q3 25 | $171.7M | $-54.1M | ||
| Q2 25 | $124.8M | $-148.8M | ||
| Q1 25 | $81.3M | $39.0M | ||
| Q4 24 | $145.8M | $153.3M | ||
| Q3 24 | $204.0M | $5.8M | ||
| Q2 24 | $235.3M | $-23.5M | ||
| Q1 24 | $106.9M | $400.0K |
自由现金流率AVTRBRKR
| Q4 25 | 7.0% | 21.2% | ||
| Q3 25 | 10.6% | -6.3% | ||
| Q2 25 | 7.4% | -18.7% | ||
| Q1 25 | 5.1% | 4.9% | ||
| Q4 24 | 8.6% | 15.6% | ||
| Q3 24 | 11.9% | 0.7% | ||
| Q2 24 | 13.8% | -2.9% | ||
| Q1 24 | 6.4% | 0.1% |
资本支出强度AVTRBRKR
| Q4 25 | 2.1% | 2.3% | ||
| Q3 25 | 2.2% | 2.4% | ||
| Q2 25 | 1.8% | 2.7% | ||
| Q1 25 | 1.8% | 3.2% | ||
| Q4 24 | 1.6% | 3.7% | ||
| Q3 24 | 2.4% | 3.8% | ||
| Q2 24 | 2.7% | 3.1% | ||
| Q1 24 | 2.1% | 3.0% |
现金转化率AVTRBRKR
| Q4 25 | 2.91× | 8.84× | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | -16.78× | ||
| Q1 25 | 1.69× | 3.74× | ||
| Q4 24 | 0.35× | 13.87× | ||
| Q3 24 | 4.24× | 0.94× | ||
| Q2 24 | 3.03× | 0.14× | ||
| Q1 24 | 2.34× | 0.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
